Pfizer的Braftovi与其他药物一起,极大地促进了转移性直肠癌患者的生存。 Pfizer's Braftovi, combined with other drugs, significantly boosts survival in metastatic colorectal cancer patients.

Pfizer的药物Braftovi与cetuximab和mFOLFOX6相结合,表明具有转移性直肠癌和BRAF V600E突变的病人的存活率有了显著提高。 Pfizer's drug Braftovi, when combined with cetuximab and mFOLFOX6, showed significant improvements in survival rates for patients with metastatic colorectal cancer and a BRAF V600E mutation. 第三阶段试验的积极成果导致林业发展局于2024年12月加速批准,将在今后的一次医疗会议上提交全部数据。 The positive results from the Phase 3 trial led to the FDA granting accelerated approval in December 2024, and the full data will be presented at a future medical meeting. 这种成功可以扩大Braftovi的使用范围,使其超出对黑瘤的初步核准范围。 This success could expand Braftovi's use beyond its initial approval for melanoma.